|
|
|
07.08.25 - 08:03
|
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target (GlobeNewswire EN)
|
|
|
BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall's selection of a second target aimed at dermatological indications....
|
|
|
04.08.25 - 13:03
|
Corporate News: Biotest AG (EQS)
|
|
|
Die Biotest AG erhält ein Einberufungsverlangen von Grifols S.A. für eine außerordentliche Hauptversammlung...
|
|
|
|
|
|
|
|
|
|
|
25.07.25 - 07:15
|
Almirall H1 2025 Results (Business Wire)
|
|
|
Almirall Continues to Deliver on its Long-Term Growth Strategy with Net Sales Growth of 12.7% in H1 2025, Driven by a Strong European Dermatology Business and Increasing Biologics Sales
Solid growth trajectory maintained: H1 net sales increased by 12.7% to €560.5 million, with EBITDA reaching €121.8 million (+16.6% YoY), driven by the strong performance of the biologics portfolio and operational excellence.
Biologics as key growth drivers: Ebglyss® achieved net sales of €44.9 million (>4x YoY) across 14 European countries. Ilumetri® continued its steady growth with a 12.7% increase in sales YoY, totaling €113.3 million in H1.
Sustained strong performance in Europe: Almirall's broad product portfolio underpins its leadership in medical dermatology, led by continued growth of Wynzora® (€17.1 million, +32.6% YoY) and Klisyri® (€13.7 million, +25.7% YoY).
Full-year guidance 2025 and mid-term outlook confirmed: Double-digit net sales growth and EBITDA targets remain on track, supported by robu...
|
|
|
|
|
|
|
|
|
14.07.25 - 14:03
|
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA3071804 and IL272092, titled “Methods of treating behavior alterations”, related to vafidemstat, Oryzon's LSD1 inhibitor in clinical development for the treatment of psychiatric disorders....
|
|
|
|
|
25.06.25 - 14:03
|
ORYZON to Host Virtual KOL Event on July 9, 2025 (GlobeNewswire EN)
|
|
|
To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat's Phase III PORTICO-2 trial in BPD To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat's Phase III PORTICO-2 trial in BPD...
|
|
|
|
|
23.06.25 - 14:03
|
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it has submitted the clinical trial protocol for its Phase III PORTICO-2 trial to the U.S. Food and Drug Administration (FDA) to initiate a registrational trial to evaluate vafidemstat in patients with Borderline Personality Disorder (BPD). The PORTICO-2 trial builds upon the encouraging results observed in the previous PORTICO Phase IIb study, where vafidemstat demonstrated significant and clinically meaningful reductions in secondary endpoints measuring aggression and overall BPD improvement. Aggression is a key symptom domain in BPD that currently represents a major unmet medical need and will be the primary endpoint in PORTICO-2. Vafidemstat, an orally active LSD1 inhibitor with a novel epigenetic mechanism of action, has shown a favorable safety and tolerability profile across multip...
|
|
|
17.06.25 - 14:03
|
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29 (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its Chief Scientific Officer, Dr. Jordi Xaus will be attending the 2025 Phelan-McDermid Syndrome Congress in Barcelona on June 26-29, which comprises the CureSHANK 2nd Annual Phelan-McDermid Syndrome Drug Development Symposium (PMSDDS2025) and the III Scientific Conference of the Spanish Phelan-McDermid Syndrome Association. Dr. Xaus will participate in a panel discussion within PMSDDS2025 entitled “Industry Perspectives Discussion”, as part of the morning session “Noncommercial & Commercial Clinical Trials and Business Considerations”, on June 27....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
